Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Penna, C.
Right arrow Articles by Nordlinger, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Penna, C.
Right arrow Articles by Nordlinger, B.
Related Collections
Right arrow Oncology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Medical Bulletin 64:127-140 (2002)
© 2002 The British Council

Surgery of liver metastases from colorectal cancer: new promises

Christophe Penna and Bernard Nordlinger

Department of Digestive and Oncologic Surgery, Ambroise Paré's Hospital, Boulogne, France

For a long time, patients with liver metastases from colorectal cancer were considered to be incurable. Over the last 30 years, the benefits of surgical resection and systemic chemotherapy have been established. Actually, surgical resections are feasible with a very low mortality and a 5-year survival that approaches 40%, but only 10–20% of patients are candidates for surgery. The others gain benefit from chemotherapy with increasingly active drugs. To improve this overall picture, efforts have been made to increase the number of patients that could be candidates for surgery and to decrease the risk of recurrence after surgical resection. Shrinkage of tumours after administration of pre-operative chemotherapy and the availability of ablative techniques now allow the treatment, with curative intent, of metastases initially considered as non-resectable. Chemotherapeutic regimens have been developed to decrease the risk of postoperative recurrence.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
J.-S. Jeong, S.-W. Lee, S.-H. Hong, Y.-J. Lee, H.-I. Jung, K.-S. Cho, H.-H. Seo, S.-J. Lee, S. Park, M.-S. Song, et al.
Antitumor Effects of Systemically Delivered Adenovirus Harboring Trans-Splicing Ribozyme in Intrahepatic Colon Cancer Mouse Model
Clin. Cancer Res., January 1, 2008; 14(1): 281 - 290.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Liersch, J. Meller, B. Kulle, T. M. Behr, P. Markus, C. Langer, B. M. Ghadimi, W. A. Wegener, J. Kovacs, I. D. Horak, et al.
Phase II Trial of Carcinoembryonic Antigen Radioimmunotherapy With 131I-Labetuzumab After Salvage Resection of Colorectal Metastases in the Liver: Five-Year Safety and Efficacy Results
J. Clin. Oncol., September 20, 2005; 23(27): 6763 - 6770.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.